drugset / Trial / NCT00306267
A Study of PROCRIT (Epoetin Alfa) 80,000 Units (U) Once Every Four Weeks (Q4W) vs. 40,000 U Once Every Two Weeks (Q2W) in Cancer Patients Not Receiving Chemotherapy
Phase 2
Terminated
61 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Ortho Biotech Products, L.P. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety and effectiveness of PROCRIT (Epoetin alfa) administered by injection subcutaneously (SC, under the skin), at a dose of 80,000 U once every four weeks or 40,000 U once every two in anemic patients with cancer not receiving chemotherapy or radiation therapy.
Timeline
- Start
- 2006-03
- Primary completion
- —
- Completion
- 2007-05
Outcome
Outcome not reported
Stopped: “Study stopped as it would not address important survival concerns raised in other recently conducted clinical studies.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | epoetin alfa | Protein / enzyme biologic | 40000 iu | Subcutaneous |
| Subject | epoetin alfa | Protein / enzyme biologic | 80000 iu | Subcutaneous |